PT-141 (bremelanotide): selected references HeartPep literature library, reviewed 2026-11-09 https://heartpep.com/us/research/library/pt-141 1. Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials Obstetrics & Gynecology. DOI: https://doi.org/10.1097/AOG.0000000000003500 PMID: 31599840 Source: https://pubmed.ncbi.nlm.nih.gov/31599840/ Verification: Full text. 2. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction International Journal of Impotence Research. DOI: https://doi.org/10.1038/sj.ijir.3901139 PMID: 14963471 Source: https://pubmed.ncbi.nlm.nih.gov/14963471/ Verification: Abstract / bibliographic record. 3. Simon JA, Kingsberg SA, Portman D, et al. (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder Obstetrics & Gynecology. DOI: https://doi.org/10.1097/AOG.0000000000003514 PMID: 31599847 Source: https://pubmed.ncbi.nlm.nih.gov/31599847/ Verification: Abstract / bibliographic record. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.